Yonsei releases promising P1 results of KRAS G12C-targeted therapy for NSCLC
A research team from Yonsei Cancer Center has published impressive results from a phase 1 clinical trial of a next-generation KRAS G12C targeted therapy. The trial demonstrated an objective response rate of 70 percent in lung cancer patients. The study …